AlzeCure Pharma AB

ALZCUR.ST

Biotechnology · Healthcare

Exchange

Stockholm Stock Exchange

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Winston Score History

The full picture

AlzeCure Pharma is a Swedish drug development company focused on building treatments for diseases that affect the brain and nervous system. Its main research targets are Alzheimer's disease, pain, and other neurological conditions. The company has not yet brought a product to market and is still in the clinical and preclinical stages of drug development.

AlzeCure does not currently generate product revenue, which explains its zero gross margin. It funds its operations through grants, partnerships, and capital raises from investors. The company is based in Stockholm, Sweden, and operates at a small scale typical of early-stage biotech firms. Its pipeline includes drug candidates in the NeuroRestore and ACD platforms, but the central risk is that most experimental drugs fail before reaching patients, and the company will likely need to raise more money to keep its research going.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

-72.7% YoY

YoY Growth Rate

Earnings declining

Insider Activity

24.6%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~6 months

kr 33M cash & investments

Short runway — potential dilution ahead through share issuance

Cash watch

AlzeCure Pharma AB has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

—

Data not available

Profit after running costs

Operating Margin

N/A

—

Data not available

Return on the money invested

ROCE

-560.4%

Weak — -560.4% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

—

Data not available

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

5/8 quarters

Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial